COMMUNIQUÉS West-GlobeNewswire

Joybird’s Treehouse to Host Free Webinar on Academic Success for Underserved Students
07/07/2025
Joybird’s Treehouse Announces Free Webinar to Improve Academic Outcomes for Underserved Students Dallas, TX , July 07, 2025 (GLOBE NEWSWIRE) -- Joybird’s Treehouse , a culturally responsive education platform founded by [...]
The American Society of Pain and Neuroscience (ASPN) Publishes Consensus Guidelines for the Use of 60-Day Peripheral Nerve Stimulation (PNS) Therapy, Highlighting Strong Clinical Applications for SPR® SPRINT® PNS
07/07/2025
CLEVELAND, July 07, 2025 (GLOBE NEWSWIRE) -- Recently, ASPN published the first clinical guidelines focused specifically on the use of 60-day PNS (SPRINT PNS), offering evidence-based best practice recommendations. It [...]
Corza Medical Announces the Launch of the Expanded Onatec Ophthalmic Suture Portfolio
07/07/2025
PARSIPPANY, New Jersey, July 07, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a leading global medical technology company, today announced the launch of its expanded Onatec Ophthalmic Suture Portfolio. This marks a [...]
Skin Care and Laser Physicians of Beverly Hills Welcomes Double Board-Certified Dermatologist
07/07/2025
Dr. Cory Kosche Brings His Expertise to the Los Angeles-Based Skin Care Team LOS ANGELES, July 07, 2025 (GLOBE NEWSWIRE) -- Skin Care and Laser Physicians of Beverly Hills are proud to introduce the newest addition to [...]
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
07/07/2025
– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at [...]
Nudj Health Appoints Dr. Padmaja Patel as Chief Medical Officer to Advance Lifestyle Medicine Services
07/07/2025
PASADENA, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Nudj Health, the leading AI-powered lifestyle medicine services company, is proud to announce the appointment of Dr. Padmaja Patel as Chief Medical Officer of [...]
Synfini Adds $8.9 Million Discovery Funding to Speed Small Molecule Drug Development
07/07/2025
Innovative System Combines Physical and Virtual Chemistry with Discovery-Focused AI and Robotic Automation to Find Better Molecules Faster and Less Expensively MENLO PARK, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- [...]
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
07/07/2025
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
07/07/2025
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months [...]
Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment
07/07/2025
THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
07/07/2025
Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658 Patents derived from AI-led analysis conducted in partnership with Sarborg Limited [...]
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
07/07/2025
Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 [...]
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
07/07/2025
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual [...]
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
07/07/2025
PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Extendicare Announces Timing of 2025 Second Quarter Results and Conference Call
07/07/2025
MARKHAM, Ontario, July 07, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the second quarter of 2025 after market [...]
Inspire Medical Systems, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025
07/07/2025
MINNEAPOLIS, July 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2025 after the close of trading on Monday, August 4. Inspire’s [...]
JenaValve's Trilogy™ THV System Procedures Live Broadcast at New York Valves 2025
07/07/2025
IRVINE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the New York Valves 2025 [...]
Collegium Announces $150 Million Share Repurchase Program
07/07/2025
STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical [...]
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
07/07/2025
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval Tividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into the brain [...]

Pages